Inhibition of monoamine oxidase-B by selegiline reduces cigarette smoke-induced oxidative stress and inflammation in airway epithelial cells

Toxicol Lett. 2017 Feb 15:268:44-50. doi: 10.1016/j.toxlet.2017.01.005. Epub 2017 Jan 17.

Abstract

Chronic obstructive pulmonary disease (COPD) is caused by the build-up of oxidative stress-induced damages due to cigarette smoking, but how monoamine oxidase (MAO)-B signaling is involved remains unclear. This study aims to establish the involvement of MAO-B signaling pathways in cigarette smoke medium (CSM)-induced oxidative stress and inflammation in human airway epithelial cells (AECs). CSM treatment increased MAO-B activity, ROS levels and IL-8 release in AECs. Pretreatment with MAO-B selective inhibitor selegiline reversed the CSM-induced changes in MAO-B activity, ROS levels and IL-8 release in a dose-dependent manner. Selegiline also reversed CSM-induced changes of anti-oxidant enzymes superoxide dismutase (SOD) and catalase (CAT) activities, GSH/GSSG ratio, as well expression of heme oxygenase-1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1). The effects of selegiline are partially driven through the nuclear factor erythroid 2 related factor 2 (Nrf2) and cytosol translocation of its negative regulator, BTB and CNC homolog 1 (Bach1). Nevertheless, selegiline fully reversed the CSM-induced effects on IKK, cytoplasmic IκB expression, and nuclear translocation of nuclear factor-κB (NF-κB) p65 subunit. Our study demonstrated that in AECs, inhibition of MAO-B using selegiline reversed the CSM-induced oxidative stress and inflammation. These data may provide a novel strategy for therapy in COPD.

Keywords: Airway epithelium; Cigarette smoke medium; Inflammation; Monoamine oxidase; Oxidative stress; Selegiline.

MeSH terms

  • Anti-Inflammatory Agents / pharmacology*
  • Antioxidants / pharmacology*
  • Bronchi / drug effects*
  • Bronchi / enzymology
  • Bronchi / pathology
  • Cell Line
  • Cytoprotection
  • Dose-Response Relationship, Drug
  • Epithelial Cells / drug effects*
  • Epithelial Cells / enzymology
  • Epithelial Cells / pathology
  • Humans
  • Inflammation Mediators / metabolism
  • Interleukin-8 / metabolism
  • Monoamine Oxidase / metabolism*
  • Monoamine Oxidase Inhibitors / pharmacology*
  • NF-kappa B / metabolism
  • Oxidative Stress / drug effects*
  • Pneumonia / enzymology
  • Pneumonia / pathology
  • Pneumonia / prevention & control*
  • Pulmonary Disease, Chronic Obstructive / enzymology
  • Pulmonary Disease, Chronic Obstructive / pathology
  • Pulmonary Disease, Chronic Obstructive / prevention & control
  • Reactive Oxygen Species / metabolism
  • Selegiline / pharmacology*
  • Signal Transduction / drug effects
  • Smoke / adverse effects*
  • Smoking / adverse effects*

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • CXCL8 protein, human
  • Inflammation Mediators
  • Interleukin-8
  • Monoamine Oxidase Inhibitors
  • NF-kappa B
  • Reactive Oxygen Species
  • Smoke
  • Selegiline
  • Monoamine Oxidase